Fig. 2From: A double-blind, randomized, placebo-controlled trial studying the effects of Saccharomyces boulardii on the gastrointestinal tolerability, safety, and pharmacokinetics of miglustatSubject disposition. *All-treated set, N = 42; PP set, N = 34. Five patients discontinued prematurely and three subjects had a compliance rate <80 % Back to article page